Table 1.
HIV-1 and HBV Activity of Lysogenic Phospholipids 9 and 12a–e Compared to TDF, 1, and DTE–TFVa
| HIV-1 | HBV | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| compd | EC50b (PBMCs) | CC50c (PBMCs) | TI (CC50/EC50) | EC50b (HepG2) | CC50c (HepG2) | TI (CC50/EC50) |
| TDF | 0.0046 | 43.7 | 9500 | 0.34 | 64.5 | 190 |
| TFV | 0.319 | >100 | >300 | |||
| 9 | 18.6 | >100.0 | >5.38 | 41.9 | >100.0 | >2.4 |
| DTE–TFV | 1.61 | >100.0 | >62.1 | 11.6 | >100.0 | >8.6 |
| 12a | 0.085 | >50.0 | >590 | >50.0 | >50.0 | >1 |
| 12b | 0.0030 | 25.0 | 8300 | 1.67 | >50.0 | >30 |
| 12c | 0.00050 | 14.0 | 28000 | 0.444 | >25 | >56 |
| 12d | 0.00065 | 14.3 | 22000 | 0.020 | >25 | >1200 |
| 1 | 0.02 | >100.0 | >5000 | |||
| 12e | 0.00060 | 6.36 | 11000 | 0.505 | >50 | >50 |
a
All data represent an average of triplicate experiments.
b
EC50, effective concentration (in μM) required to inhibit HIV-1 or HBV by 50%.
c
CC50, effective concentration (in μM) required to reduce the viability of uninfected cells by 50%.